1-((3S,4R)-4-(3-FLUOROPHENYL)-1-(2-METHOXYETHYL)PYRROLIDIN-3-YL)-3-(4-METHYL-3-(2-METHYLPYRIMIDIN-5-YL)-1-PHENYL-1H-PYRAZOL-5-YL)UREA AS A TRKA KINASE INHIBITOR
Provided is Compound (I) or a pharmaceutically acceptable salt thereof, which is an inhibitor of TrkA kinase and is useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation and inflammatory diseases, neurodegenerative diseases, certain...
Saved in:
Main Authors | , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
21.03.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Provided is Compound (I) or a pharmaceutically acceptable salt thereof, which is an inhibitor of TrkA kinase and is useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation and inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, pelvic pain syndrome, diseases related to an imbalance of the regulation of bone remodeling, and diseases resulting from Connective Tissue Growth Factor aberrant signaling.
La présente invention concerne le composé (I) ou un sel pharmaceutiquement acceptable correspondant, qui est un inhibiteur de la kinase TrkA et qui est utile dans le traitement de maladies qui peuvent être traitées par un inhibiteur de la kinase TrkA, telles que la douleur, le cancer, l'inflammation et les maladies inflammatoires, les maladies neurodégénératives, certaines maladies infectieuses, le syndrome de Sjogren, l'endométriose, la neuropathie périphérique diabétique, la prostatite, le syndrome de la douleur pelvienne, les maladies liées à un déséquilibre de la régulation du remodelage osseux et les maladies résultant d'une signalisation aberrante du facteur de croissance du tissu conjonctif. |
---|---|
Bibliography: | Application Number: CA20152949160 |